Adjuvant chemoembolization offers benefit in HCC with microvascular invasion

  • Eur J Surg Oncol

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A meta-analysis shows that adjuvant transarterial chemoembolization (TACE) is associated with a survival benefit in hepatocellular carcinoma (HCC) with microvascular invasion (MVI).

Why this matters

  • There is no currently recommended postoperative treatment for HCC with MVI.
  • The study is the first systematic review and meta-analysis to compare resection with and without adjuvant TACE  in HCC with MVI.

Study design

  • Systematic review and meta-analysis of 12 studies (n=2190).
  • Funding: Various nonindustry sources.

Key results

  • In a meta-analysis of 10 studies, TACE was associated with better OS than resection alone at 1 year (OR, 0.33; P<.001 years p and>
  • In a meta-analysis of 11 studies, TACE was associated with better DFS at 1 year (OR, 0.45; P<.001 years p and>
  • A subgroup analysis of 4 studies that included tumors >5 cm showed better survival with TACE at:
    • 1 year (OS: OR, 0.29 [P<.001 or>
    • 3 years (OS: OR, 0.45 [P<.001 or>
    • 5 years (OS: OR, 0.38 [P=.001]; DFS: OR, 0.42 [P=.013]).

Limitations

  • Only 1 study was a randomized controlled trial.
  • All studies were conducted in China.